Snake antivenoms

Journal of Toxicology - Clinical Toxicology

Volumn 41, Issue 3, 2003, Pages 277-290

  Lalloo, David G ^a   Theakston, R David G ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SNAKE VENOM ANTISERUM;

ANAPHYLAXIS; ARTHRALGIA; BLEEDING; BLOOD CLOTTING; BRONCHOSPASM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENVENOMATION; FEVER; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; LYMPHADENOPATHY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; PROTEINURIA; PRURITUS; REVIEW; SERUM SICKNESS; SHOCK; URTICARIA;

ANIMALS; ANTIVENINS; HUMANS; SNAKE BITES; SNAKE VENOMS;

SERPENTES;

EID: 0037646902     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.1081/CLT-120021113     Document Type: Review

References (121)

1. Sewall H. Experiments on the preventative inoculation of rattlesnake venom. J Physiol 1887; 8:203.
2. Calmette A. Contribution a l'etude des venins. Ann Inst Pasteur 1895; 9:225-251.
3. Russell FE. Snake venom immunology: historical and practical considerations. J Toxicol-Toxin Rev 1988; 7:1-82.
4. Sutherland SK. Antivenom research in Australia. Med J Aust 1994; 161:48-50.
5. Pope CG. The action of proteolytic enzymes on the antitoxins and proteins in immune sera. Br J Exp Pathol 1939; 20:132-149.
6. Russell FE, Sullivan JB, Egen NB, Jeter WS, Markland FS, Wingert WA, Bar-Or D. Preparation of a new antivenin by affinity chromatography. Am J Trop Med Hyg 1985; 34(1):141-150.
7. 2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. Toxicon 1989; 27(3):297-303.
8. Otero R, Gutierrez JM, Rojas G, Nunez V, Diaz A, Miranda E, Uribe AF, Silva JF, Ospina JG, Medina Y, Toro MF, Garcia ME, Leon G, Garcia M, Lizano S, De La TJ, Marquez J, Mena Y, Gonzalez N, Arenas LC, Puzon A, Blanco N, Sierra A, Espinal ME, Lozano R. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999; 37(6):895-908.
9. Kiem, TX. The production of Calloselasma rhodostoma antivenom (C.R.A.V.) from egg yolk of hens immunized with venom: its application for treatment of snake bite patients in Vietnam. Proceedings of the XIIIth World Congress of the International Society of Toxinology, Paris, 2000.
10. Theakston RD, Warrell DA. Crisis in snake antivenom supply for Africa. Lancet 2000; 356(9247):2104.
11. Lalloo DF, Theakston RD, Warrell DA. The African challenge. Lancet 2002; 359(9316):1527.
12. Smith DC, Reddi KR, Laing G, Theakston RG, Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30(8):865-871.
13. Thalley BS, Carroll SB. Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens. Biotechnology (NY) 1990; 8(10):934-938.
14. Carroll SB, Thalley BS, Theakston RD, Laing G. Comparison of the purity and efficacy of affinity purified avian antivenoms with commercial equine crotalid antivenoms. Toxicon 1992; 30(9):1017-1025.
15. Smith TW, Lloyd BL, Spicer N, Haber E. Immunogencity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol 1979; 36:384-396.
16. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab′)2. Toxicol Appl Pharmacol 1998; 150(2):295-300.
17. Pepin S, Lutsch C, Grandgeorge M, Scherrmann JM. Snake F(ab′)2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pharm Res 1995; 12(10):1470-1473.
18. Ismail M, Abd-Elsalam MA. Pharmacokinetics of 125I-labelled IgG, F(ab′)2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Toxicon 1998; 36(11):1523-1528.
19. Ismail M, Abd-Elsalam MA, Al Ahaidib MS. Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB′)2 and F(AB) of the antivenin. Toxicon 1998; 36(1):93-114.
20. Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, Phillips RE, Warrell DA. Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 1990; 42(3):260-266.
21. Riviere G, Choumet V, Audebert F, Sabouraud A, Debray M, Scherrmann JM, Bon C. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J Pharmacol Exp Ther 1997; 281(1):1-8.
22. Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon 1998; 36(6):823-846.
23. Seifert SA, Boyer LV. Recurrence phenomena after immunoglobulin therapy for snake envenomations: part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies. Ann Emerg Med 2001; 37(2):189-195.
24. Nielsen H, Sorensen H, Faber V, Svehag SE. Circulating immune complexes, complement activation kinetics and serum sickness following treatment with heterologous anti-snake venom globulin. Scand J Immunol 1978; 71(1):25-33.
25. Ownby CL, Reisbeck SL, Allen R. Levels of therapeutic antivenin and venom in a human snakebite victim. South Med J 1996; 89(8):803-806.
26. Thein T, Kyi T, Mg MT. Plasma clearance time of Russell's viper (Vipera russelli) antivenom in human snake bite victims. Trans R Soc Trop Med Hyg 1985; 79(2):262-263.
27. Meyer WP, Habib AG, Onayade AA, Yakubu A, Smith DC, Nasidi A, Daudu IJ, Warrell DA, Theakston RD. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom. Am J Trop Med Hyg 1997; 56(3):291-300.
28. Ariaratnam CA, Meyer WP, Perera G, Eddleston M, Kuleratne SA, Attapattu W, Sheriff R, Richards AM, Theakston RD, Warrell DA. A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia russelii russelii): a preliminary dose-finding and pharmacokinetic study. Am J Trop Med Hyg 1999; 61(2):259-265.
29. Riviere G, Choumet V, Saliou B, Debray M, Bon C. Absorption and elimination of viper venom after antivenom administration. J Pharmacol Exp Ther 1998; 285(2):490-495.
30. Bauer RJ, Leigh SD, Birr CA, Bernhard SL, Fang M, Der K, Ihejeto NO, Carroll SF, Kung AH. Alteration of the pharmacokinetics of small proteins by iodination. Biopharm Drug Dispos 1996; 17(9):761-774.
31. Audebert F, Urtizberea M, Sabouraud A, Scherrmann JM, Bon C. Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits. J Pharmacol Exp Ther 1994; 268(3):1512-1517.
32. Karlson-Stiber C, Persson H, Heath A, Smith D, al Abdulla IH, Sjostrom L. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J Intern Med 1997; 241(1):53-58.
33. Theakston RD. An objective approach to antivenom therapy and assessment of first-aid measures in snake bite. Ann Trop Med Parasitol 1997; 91(7):857-865.
34. Pepin-Covatta S, Lutsch C, Lang J, Scherrmann JM. Preclinical assessment of immunoreactivity of a new purified equine F(ab′)2 against European viper venom. J Pharm Sci 1998; 87(2):221-225.
35. Ariaratnam CA, Sjostrom L, Raziek Z, Kularatne SA, Arachchi RW, Sheriff MH, Theakston RD, Warrell DA. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii). Trans R Soc Trop Med Hyg 2001; 95(1):74-80.
36. Cardoso JLC, Fan HW, Franca FOS, Jorge MT, Leite RP, Nishioka SA, Avila A, Sano-Martins IS, Tomy SC, Santoro ML, Chudzinski AM, Castro SCB, Kamiguti AS, Kelen EMA, Hirata MH, Mirandola RMS, Theakston RDG, Warrell DA. Randomized comparitive trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil. Q J Med 1993; 86:315-325.
37. Corrigan P, Russell FE, Wainschel J. Clinical reactions to antivenin. Toxicon 1978; 16(suppl 1):457-465.
38. Reid HA. Antivenom reactions and efficacy. Lancet 1980; 1(8176):1024-1025.
39. Malasit P, Warrell DA, Chanthavanich P, Viravan C, Mongkolsapaya J, Singhthong B, Supich C. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br Med J (Clin Res Ed) 1986; 292(6512):17-20.
40. Sutherland SK. Serum reactions: an analysis of commercial antivenoms and the possible role of anticomplementary activity in de novo reactions to antivenom and venom. Med J Aust 1977; I:613-615.
41. Pugh RN, Theakston RD. Antivenom reactions and complement depletion in snake bite. Ann Trop Med Parasitol 1987; 81(1):73-75.
42. Theakston RDG, Smith DC. Antivenoms. A review of current status and future developments. Biopharmaceuticals 1997; 7:366-375.
43. Leon G, Monge M, Rojas E, Lomonte B, Gutierrez JM. Comparison between IgG and F(ab′)(2) polyvalent antivenoms: neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon 2001; 39(6):793-801.
44. Morais JF, de Freitas MC, Yamaguchi IK, dos Santos MC, da Silva WD. Snake antivenoms from hyperimmunized horses: comparison of the antivenom activity and biological properties of their whole IgG and F(ab′)2 fragments. Toxicon 1994; 32(6):725-734.
45. Otero-Patino R, Cardoso JL, Higashi HG, Nunez V, Diaz A, Toro MF, Garcia ME, Sierra A, Garcia LF, Moreno AM, Medina MC, Castaneda N, Silva-Diaz JF, Murcia M, Cardenas SY, Dias da Silva WD. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Uraba, Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). Am J Trop Med Hyg 1998; 58(2):183-189.
46. Dart RC, McNally J. Efficacy, safety and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181-188.
47. Nuchpraryoon I, Garner P. Interventions for preventing reactions to snake antivenom. Cochrane Database Syst Rev 2000; (2):CD002153.
48. Sutherland SK. Snakebites and antivenoms. Aust Prescriber 1979; 3(4):84-87.
49. Fan HW, Marcopito LF, Cardoso JL, Franca FO, Malaque CM, Ferrari RA, Theakston RD, Warrell DA. Sequential randomized and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites. Br Med J 1999; 318(7196):1451-1452.
50. Premawardhena AP, de Silva CE, Fonseka MM, Gunatilake SB, de Silva HJ. Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomized, placebo controlled trial. Br Med J 1999; 318(7190):1041-1043.
51. Sutherland SK. Fatal cerebral haemorrhage after tiger bite. Med J Aust 1991; 155:280.
52. Currie BJ, Hudson BJ. Fatal cerebral haemorrhage after tiger snake bite. Med J Aust 1991; 155:280.
53. Currie BJ. Snakebite in tropical Australia, Papua New Guinea and Irian Jaya. Emerg Med 2000; 12:285-294.
54. Dassanayake AS, Karunanayake P, Kasturiratne KT, Fonseka MM, Wijesiriwardena B, Gunatilake SB, de Silva HJ. Safety of subcutaneous adrenaline as prophylaxis against acute adverse reactions to antivenom serum in snakebite. Ceylon Med J 2002; 47(2):48-49.
55. WHO. Progress in the characterisation of venoms and the standardization of antivenoms. No 58ed. WHO offset publications, 1981.
56. Theakston RDG. Characterisation of venoms and standardisation of antivenoms. In: Harris JB, ed. Natural Toxins. Oxford: Clarendon Press, 1986:287-303.
57. Gutierrez JM, Rojas G, Lomonte B, Gene JA, Chaves F, Alvarado J, et al. Standardisation of assays for testing the neutralizing ability of antivenoms. Toxicon 1990; 28:1127-1129.
58. Theakston RD, Lloyd-Jones MJ, Reid HA. Micro-ELISA for detecting and assaying snake venom and venom-antibody. Lancet 1977; 2(8039):639-641.
59. Warrell DA, Warrell MJ, Edgar W, Prentice CRM, Mathison J, Mathison J. Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). Br Med J 1980; 1:607-614.
60. Warrell DA, Looareesuwan S, Theakston RDG, Phillips RE, Chanthavanich P, Viravan C, Supanaranond W, Karbwang J, Ho M, Hutton RA, Vejcho S. Randomised comparative trial of three monospecific antivenoms for bites by the Malayan Pit viper (Calloselasma rhodostoma) in Southern Thailand; clinical and laboratory correlations. Am J Trop Med Hyg 1986; 35:1235-1247.
61. Leon G, Rojas G, Lomonte B, Gutierrez JM. Immunoglobulin G and F(ab′)2 polyvalent antivenoms do not differ in their ability to neutralize hemorrhage, edema and myonecrosis induced by Bothrops asper (terciopelo) snake venom. Toxicon 1997; 35(11):1627-1637.
62. Leon G, Valverde JM, Rojas G, Lomonte B, Gutierrez JM. Comparative study in the ability of IgG and Fab sheep antivenoms to neutralize local hemorrhage, edema and myonecrosis induced by Bothrops asper snake venom. Toxicon 2000; 38:233-244.
63. Lomonte B, Leon G, Hanson LA. Similar effectiveness of Fab and F(ab′)2 antivenoms in the neutralization of hemorrhagic activity of Vipera berus snake venom in mice. Toxicon 1996; 34(10):1197-1202.
64. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med 1996; 27(3):321-326.
65. Warrell DA, Davidson NM, Greenwood BM, Ormerod LD, Pope HM, Watkins BJ, Prentice CRM. Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Q J Med 1977; 181:33-62.
66. Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, McNally J, Kitchens CS, Curry SC, Bogdan GM, Ward SB, Porter RS. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161(16):2030-2036.
67. Reid HA. Cobra bites. Br Med J 1964; 2:540-545.
68. Warrell DA, Greenwood BM, Davidson NM, Ormerod LD, Prentice CRM. Necrosis, haemorrhage and complement depletion following bites by the spitting cobra. Q J Med 1976; 45(177):1-22.
69. Pochanugool C, Wildde H, Bhanganada K, Chanhome L, Cox MJ, Chaiyabutr N, Sitprija V. Venomous snakebite in Thailand. II: clinical experience. Mil Med 1998; 163(5):318-323.
70. Russell FE, Ruzic N, Gonzalez H. A new method for quantitating hemorrhage induced by rattlesnake venoms. Toxicon 1985; 23(2):201-207.
71. Karlson-Stiber C, Persson H. Antivenom treatment in Vipera berus envenoming-report of 30 cases. J Intern Med 1994; 235(1):57-61.
72. Jorge MT, Cardoso JL, Castro SC, Ribeiro L, Franca FO, de Almeida ME, Kamiguti AS, Santo-Martins IS, Santoro ML, Mancau JE. A randomized 'blinded' comparison of two doses of antivenom in the treatment of Bothrops envenoming in Sao Paulo, Brazil. Trans R Soc Trop Med Hyg 1995; 89(1):111-114.
73. Lalloo DG, Trevett AJ, Korinhona A, Nwokolo N, Laurenson IF, Paul M, et al. Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom. Am J Trop Med Hyg 1995; 52(6):525-531.
74. Lalloo DG, Trevett AJ, Owens D, Minei J, Naraqi S, Saweri A, Hutton R, Theakston RDG, Warrell DA. Coagulopathy following bites by the Papuan Taipan (Oxyuranus scutellatus canni). Blood Coagul Fibrinolysis 1995; 6(1):65-72.
75. Chippaux JP, Lang J, Eddine SA, Fagot P, Rage V, Peyrieux JC, Le MV. Clinical safety of a polyvalent F(ab′)2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Trans R Soc Trop Med Hyg 1998; 92(6):657-662.
76. Cull-Candy SG, Fohlman J, Gustafsson D, Lüllmann-Rauch R, Thesleff S. The effects of taipoxin and notexin on the function and fine structure of the murine neuromuscular junction. Neuroscience 1976; 1:175-180.
77. Harris JB, Maltin CA. Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus scutellatus. Br J Pharmacol 1982; 76:61-75.
78. Theakston RD, Phillips RE, Warrell DA, Galagedera Y, Abeysekera DT, Dissanayaka P, De Silva A, Aloysius DJ. Envenoming by the common krait (Bungarus caeruleus) and Sri Lankan cobra (Naja naja naja): efficacy and complications of therapy with Haffkine antivenom. Trans R Soc Trop Med Hyg 1990; 84(2):301-308.
79. Simpson LL, Lautenslager GT, Kaiser II, Middlebrook JL. Identification of the site at which phospholipase A2 neurotoxins localize to produce their neuromuscular blocking effects. Toxicon 1993; 31:13-26.
80. Kularatne SA. Common krait (Bungarus caeruleus) bite in Anuradhapura, Sri Lanka: a prospective clinical study, 1996-1998. Postgrad Med J 2002; 78:276-280.
81. Campbell CH. The Death adder (Acanthophis antarcticus): the effect of the bite and its treatment. Med J Aust 1966; 2:922-925.
82. Lalloo DG, Trevett AJ, Black J, Mapao J, Saweri A, Naraqi S, Owens D, Kamiguti AS, Hutton RA, Theakston RDG, Warrell DA. Neurotoxicity, anticoagulant activity and evidence of rhabdomyolysis in patients bitten by death adders (Acanthophis sp.) in southern Papua New Guinea. Q J Med 1996; 89:25-35.
83. Watt G, Meade BM, Theakston RDG, Padre L, Tuazon ML, Calubaquib C, Santiago E, Ranoa CP. Comparison of Tensilon and antivenom for the treatment of cobrabite paralysis. Trans R Soc Trop Med Hyg 1989; 83:570-573.
84. Warrell DA, Looareesuwan S, White NJ, Theakston RD, Warrell MJ, Kosakarn W, Reid HA. Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. Br Med J (Clin Res Ed) 1983; 286(6366):678-680.
85. Watt G, Theakston RDG, Hayes CG, Yambao ML, Sangalang R, Ranoa CP, Alquizalas E, Warrell DA. Positive response to edrophonium in patients with neurotoxic envenoming by cobras (Naja naja philippinensis). N Engl J Med 1986; 315:1444-1448.
86. Currie B, Fitzmaurice M, Oakley J. Resolution of neurotoxicity with anticholinesterase therapy in death-adder envenomation. Med J Aust 1988; 148:522-525.
87. Pochanugool C, Limthongkul S, Wilde H. Management of Thai cobra bites with a single bolus of antivenin. Wilderness Environ Med 1997; 8(1):20-23.
88. Phillips RE, Theakston RD, Warrell DA, Galigedara Y, Abeysekera DT, Dissanayka P, Hutton RA, Aloysius DJ. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell's viper (Vipera russelli pulchella) in Sri Lanka: failure of Indian (Haffkine) antivenom. Q J Med 1988; 68:691-715.
89. Ramachandran S, Ganaikabahu B, Pushparajan K, De Silva CK, Wijesekera J. Myonecrosis due to Russell's viper bites in Sri Lanka. Am J Trop Med Hyg 1994; 50(5):597-601.
90. Warrell DA, Ormerod LD, Davidson NM. Bites by puff-adder (Bitis arietans) in Nigeria, and value of antivenom. Br Med J 1975; 4(5998):697-700.
91. Myint-Lwin, Warrell DA, Phillips RE, Tin-Nu-Swe, Tun-Pe, Maung-Maung-Lay. Bites by Russell's viper (Vipera russelli siamensis) in Burma: haemostatic, vascular and renal disturbances and response to treatment. Lancet 1985; 2:1259-1264.
92. Warrell DA, Arnett C. The importance of bites by the saw-scaled or carpet viper (Echis carinatus): epidemiological studies in Nigeria and a review of the world literature. Acta Trop 1976; 33:307-341.
93. Thomas L, Tyburn B, Bucher B, Pecout F, Ketterle J, Rieux D, Smadja D, Garnier D, Plumelle Y. Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific anti-venom. Research Group on Snake Bites in Martinique. Am J Trop Med Hyg 1995; 52(5):419-426.
94. Thomas L, Tyburn B, Lang J, Ketterle J. Early infusion of a purified monospecific F(ab′)2 antivenom serum for Bothrops lanceolatus bites in Martinique. Lancet 1996; 347(8998):406.
95. Tibballs J, Sutherland S. The efficacy of antivenom in prevention of cardiovascular depression and coagulopathy induced by brown snake (Pseudonaja) species venom. Anaesth Intensive Care 1991; 19:530-534.
96. Henderson A, Baldwin LN, May C. Fatal brown snake (Pseudonaja textilis) envenomation despite the use of antivenom. Med J Aust 1993; 158:709-710.
97. Masci PP, Mirtschin PJ, Nias TN, Turnbull RK, Kuchel TR, Whitaker AN. Brown snakes (Pseudonaja genus): venom yields, prothrombin activator neutralization and implications affecting antivenom usage. Anaesth Intensive Care 1998; 26(3):276-281.
98. Ho M, Warrell MJ, Warrell DA, Bidwell D, Voller A. A critical reappraisal of the use of enzyme-linked immunosorbent assays in the study of snake bite. Toxicon 1986; 24:211-221.
99. Boyer LV, Seifert SA, Clark RF, McNally JT, Williams SR, Nordt SP, Walter FG, Dart RC. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 1999; 159(7):706-710.
100. WHO, SEARO. The clinical management of snakebites in the southeast Asian region. Southeast Asian J Trop Med Public Health 1999; 30(suppl 1):1-84.
101. Gold BS, Dart RC, Barish RA. Bites of venomous snakes. N Engl J Med 2002; 347(5):347-356.
102. Meier J, White J, eds. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Boca Raton: CRC Press, 1995.
103. Warrell DA. Clinical toxicology of snakebite in Africa and the Middle East/Arabian peninsula. Handbook of Clinical Toxicology of Animal Venoms and Poisons. Boca Raton: CRC Press, 1995:433-492.
104. Nishioka SA. Limitations of the snakebite severity score. Ann Emerg Med 1996; 28(3):371-372.
105. Ho M, Warrell DA, Looareesuwan S, Phillips RE, Chanthavanich P, Karbwang J, Supanaranond W, Viravan C, Hutton RA, Vejcho S. Clinical significance of venom levels in patients envenomed by the Malayan pit viper (Calloselasma rhodostoma). Am J Trop Med Hyg 1986; 35(3):579-587.
106. Silamut K, Ho M, Looareesuwan S, Viravan C, Wuthiekan V, Warrell DA. Detection of venom by enzyme linked immunosorbent assay (ELISA) in patients bitten by snakes in Thailand. Br Med J 1987; 1:402-404.
107. Audebert F, Sorkine M, Bon C. Envenoming by viper bites in France: clinical gradation and biological quantification by ELISA. Toxicon 1992; 30(5-6):599-609.
108. Thomas L, Tyburn B, Ketterle J, Biao T, Mehdaoui H, Moravie V, Rouvel C, Plumelle Y, Bucher B, Canonge D, Marie-Nelly CA, Lang J. Prognostic significance of clinical grading of patients envenomed by Bothrops lanceolatus in Martinique. Members of the Research Group on Snake Bite in Martinique. Trans R Soc Trop Med Hyg 1998; 92(5):542-545.
109. Reid HA, Chan KE, Thean PC. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963; 1:621-626.
110. Trethewie ER, Rawlinson PA. Immunological diagnosis of type of snake in snakebite. Med J Aust 1967; 2(3):111-113.
111. Greenwood BM, Warrell DA, Davidson NM, Ormerod LD, Reid HA. Immunodiagnosis of snake bite. Br Med J 1974; 4(5947):743-745.
112. Sutherland SK, Coulter AR, Broad AJ. Human snake bite victims; the successful detection of circulating snake venom by radioimmunoassay. Med J Aust 1975; 1:27-29.
113. Theakston RDG, Lloyd-Jones MJ, Reid HA. Micro-ELISA for detecting and assaying snake venom and antibody. Lancet 1977; ii:639-641.
114. Minton SA. Present tests for the detection of snake venom: clinical applications. Ann Emerg Med 1987; 16:932-937.
115. Trevett AJ, Lalloo DG, Nwokolo NC, Theakston DG, Naraqi S, Warrell DA. Venom detection kits in the management of snakebite in Central province, Papua New Guinea. Toxicon 1995; 33(5):703-705.
116. Pugh RN, Theakston RD. A clinical study of viper bite poisoning. Ann Trop Med Parasitol 1987; 81:135-149.
117. Hutton RA, Looareesuwan S, Ho M, Silamut K, Chanthavanich P, Karbwang J, Supanaranond W, Vejcho S, Viravan C, Phillips RE, et al. Arboreal green pit vipers (genus Trimeresurus) of South-East Asia: bites by T. albolabris and T. macrops in Thailand and a review of the literature. Trans R Soc Trop Med Hyg 1990; 84:866-874.
118. Dart RC, Seifert SA, Carroll L, Clark RF, Hall E, Boyer-Hassen LV, Curry SC, Kitchens CS, Garcia RA. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning. Ann Emerg Med 1997; 30(1):33-39.
119. Theakston RD. New techniques in antivenom production and active immunization against snake venoms. Trans R Soc Trop Med Hyg 1989; 83(4):433-435.
120. Harrison RA, Richards A, Laing GD, Theakston RD. Simulataneous GeneGun immunisation with plasmids encoding antigen and GM-CSF: significant enhancement of murine antivenom IgG1 titres. Vaccine 2002; 20(13-14):1702-1706.
121. Appendix: Antivenom tables. J Toxicol Clin Toxicol 2003; 41(3):317-327.